DNTH dianthustx.com: Forward P/S Multiple
Dianthus Therapeutics develops innovative antibodies to combat inflammation through strategic biotech partnerships. The projected P/S metric allows for an assessment of market revenue expectations, and its latest value is recorded as 1893.10. Outlook depends on the safety of the DNTH103 molecule and the rate of capital burn, while geopolitical factors exert no influence on the development of the company's clinical trials.
Dianthus Therapeutics, Inc. - analytical breakdowns and key metrics (DNTH)
- current price and projected stock value:
- company stock capitalization data:
- issuer book value statistics:
- company total debt and liquidity indicators:
Debt to Equity Dianthus Therapeutics|DNTH - Long-Term Debt to Capital Ratio|Short-Term Debt to Equity Ratio Dianthus Therapeutics|DNTH - Company Cumulative Indebtedness|Debts to Book Capitalization Dianthus Therapeutics Inc|DNTH - Company Long-Term Loans and Borrowings|Company Current Liabilities Dianthus Therapeutics|Quick Liquidity dianthustx.com
- financial results and valuation multiples details:
DNTH - Net Financial Result|Future Profit Dianthus Therapeutics|DNTH - Company Value to Net Income|Projected Price to Earnings Dianthus Pharma|DNTH - Company Value to Earnings Growth Ratio|EV/EBITDA Multiple Dianthus Therapeutics Inc|DNTH - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Dianthus Therapeutics|DNTH - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months dianthustx.com|DNTH - Earnings per share increase in current year|Earnings growth forecast for next year Dianthus Therapeutics
- sales volume and revenue indicators:
General company analysis:Dianthus Pharma DNTH
Dianthus Therapeutics (DNTH) competes in the high-risk immunotherapy segment, where success depends on clinical trial results. The forward P/S ratio compares current market capitalization with expected sales volume to determine the premium for future growth. Analyzing the projected price-to-sales ratio allows for an assessment of investor appetite for financing biotech projects. The dynamics of this coefficient reflect the balance between market optimism and fundamental development risks.
Key competitors
Forward P/S Multiple ARGX (argenx.com)|BioNTech Group (BNTX) - Market Cap to Future Revenue Ratio|ABIVAX - Forward P/S Multiple|ADMA - Forward P/S Multiple|Protagonist (PTGX) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple Immunovant Inc|Price-to-Projected Revenue Ratio Kiniksa Pharmaceuticals|Grifols Group (GRFS) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Adaptive Biotechnologies Corp (ADPT)|Price-to-Projected Revenue Ratio CLDX (Celldex Therapeutics)|Price-to-Projected Revenue Ratio Aurinia Pharma AUPH|Forward Price to Sales BCRX|VERA: Forward Price-to-Revenue Multiple|PHVS - Forward P/S Multiple|ABCL: Forward P/S Multiple|TRML (Tourmaline Bio, Inc.) - Price-to-Projected Revenue Ratio|Price-to-Projected Revenue Ratio Intrexon|PHAR - Projected Price to Revenue|Forward P/S Multiple NKTR|Price-to-Projected Revenue Ratio UPB (Upstream Bio Corp)|Price-to-Projected Revenue Ratio Zenas Biopharma, Inc. ZBIO|Market Cap to Expected Sales Ratio immunome.com (IMNM)|Gossamer Bio Inc - Forward P/S Multiple|Forward Price to Sales KALV (KalVista Pharmaceuticals, Inc.)|SEPN: Forward P/S Multiple|Forward Price-to-Revenue Multiple Pieris Pharmaceuticals Inc|Forward Price-to-Revenue Multiple SVRA|Forward Price-to-Revenue Multiple Rigel Pharmaceuticals (RIGL)|Forward P/S Multiple ANAB|ATXS - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio enGene Corp ENGN|Market Cap to Expected Sales Ratio RAPT Therapeutics, Inc. (RAPT)|Aerovate - Forward P/S Multiple|ACRS - Forward P/S Multiple|KYTX (Kyverna Therapeutics) - Forward Price-to-Revenue Multiple|Market Cap to Future Revenue Ratio Tiziana Life Sciences Ltd. (TLSA)|Forward Price-to-Revenue Multiple CABA|Ventyx Biosciences (VTYX) - Market Cap to Expected Sales Ratio|Forward P/S Multiple THTX|AVTX (Avalo Therapeutics, Inc) - Forward Price to Sales|Forward P/S Multiple ELDN (eledon.com)|AGEN - Forward Price-to-Revenue Multiple|CLYM - Price-to-Projected Revenue Ratio|Future Price to Revenue ZURA|ATYR: Forward P/S Multiple|Adagene Corp (ADAG) - Forward P/S Multiple|Forward Price-to-Revenue Multiple IMA|Shattuck Labs, Inc. - Future Price to Revenue|Price-to-Projected Revenue Ratio Equillium Inc (EQ)|Forward P/S Multiple Connect Biopharma Holdings (CNTB)|Price-to-Projected Revenue Ratio Immunic, Inc. IMUX|Forward P/S Multiple Atara Biotherapeutics ATRA|IFRX - Price-to-Projected Revenue Ratio|XFOR: Price-to-Projected Revenue Ratio|ACET: Forward P/S Multiple|CELU - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio inmunebio.com|Market Cap to Projected Revenue BRNS (barinthusbio.com)|Forward P/S Multiple KZR|Forward P/S Multiple SAB Biotherapeutics, Inc (SABS)|Forward P/S Multiple AKTX (Akari Therapeutics, Plc)|Forward P/S Multiple enlivex.com ENLV|QTTB: Forward Price-to-Revenue Multiple|GOVX - Forward P/S Multiple|Edesa Biotech Inc (EDSA) - Price-to-Projected Revenue Ratio|IBIO - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio carismatx.com|XTLB: Forward Price to Sales|Price-to-Projected Revenue Ratio Bolt Biotherapeutics Inc. (BOLT)|HCW Biologics - Market Cap to Projected Revenue|Price-to-Projected Revenue Ratio aptevotherapeutics.com APVO|AIM - Forward Price-to-Revenue Multiple|Aditxt - Forward P/S Multiple|Market Cap to Expected Sales Ratio GRI Bio Corporation GRI|xortx.com (XRTX) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio reshapelifesciences.com (HIND)|Price-to-Projected Revenue Ratio Revelation Bio|Market Cap to Future Revenue Ratio Indaptus Therapeutics, Inc. INDP|Price-to-Projected Revenue Ratio BiondVax Pharmaceuticals (SCNI)|Forward Price-to-Revenue Multiple CalciMedica CALI|Price-to-Projected Revenue Ratio Affimed AFMD|ALLK - Forward Price-to-Revenue Multiple|HOOKIPA Pharma, Inc. - Forward P/S Multiple|Forward Price to Sales IGMS (igmbio.com)|ITOS (iTeos Therapeutics, Inc.) - Forward Price-to-Revenue Multiple|Ocean Biomedical Corp (OCEA) - Forward P/S Multiple|Price-to-Projected Revenue Ratio TC BioPharm (Holdings) PLC|Forward P/S Multiple thirdharmonicbio.com
